Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: An open randomized trial

American Journal of Geriatric Psychiatry

Volumn 22, Issue 4, 2014, Pages 341-348

  Freund Levi, Yvonne ^a,b   Jedenius, Erik ^a   Tysen Bäckström, Ann Christine ^b   Lärksäter, Marie ^b   Wahlund, Lars Olof ^a,b   Eriksdotter, Maria ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dementia; Galantamine; Neuropsychiatric symptoms; NPI; NPSD; Risperidone

Indexed keywords

GALANTAMINE; RISPERIDONE;

AGED; AGITATION; ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL DEMENTIA RATING; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; CONTROLLED STUDY; DEMENTIA; DRUG SAFETY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC DISORDER; MINI MENTAL STATE EXAMINATION; MUSCULOSKELETAL DISEASE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NEUROPSYCHIATRIC INVENTORY; NEUROPSYCHIATRIC SYMPTOM IN DEMENTIA; NUTRITIONAL DISORDER; OPEN STUDY; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIMPSON-ANGUS SCALE; SKIN DISEASE;

DEMENTIA; GALANTAMINE; NEUROPSYCHIATRIC SYMPTOMS; NPI; NPSD; RISPERIDONE;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CHOLINESTERASE INHIBITORS; DEMENTIA; FEMALE; GALANTAMINE; HUMANS; IRRITABLE MOOD; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR AGITATION; RISPERIDONE; TREATMENT OUTCOME;

EID: 84898622517     PISSN: 10647481     EISSN: 15457214     Source Type: Journal    
DOI: 10.1016/j.jagp.2013.05.005     Document Type: Article

References (38)

1. Wimo A, Prince M: Alzheimer's Disease International World Alzheimer Report 2010. London, Alzheimer's Disease International, 2010
2. Ballard C, Gray A, Ayre G: Psychotic symptoms, aggression and restlessness in dementia. Rev Neurol 1999; 155(suppl 4):S44eS52
3. Ballard C, Corbett A: Management of neuropsychiatric symptoms in people with dementia. CNS Drugs 2010; 24:729-739
4. Grossberg GT: The ABC of Alzheimer's disease: behavioral symptoms and their treatment. Int Psychogeriatr2002; 14(suppl 1):27-49
5. Ferris SH, Steinberg G, Shulman E, et al: Institutionalization of Alzheimer's disease patients: reducing precipitating factors through family counseling. Home Health Care Serv Q 1987; 8: 23-51
6. Pruchno RA, Michaels JE, Potashnik SL: Predictors of institutionalization among Alzheimer disease victims with caregiving spouses. J Gerontol 1990; 45:S259-S266
7. Raskind MA, Risse SC, Lampe TH: Dementia and antipsychotic drugs. J Clin Psychiatry 1987; 48(suppl):16-18
8. NICE, Dementia Supporting people with dementia and their careers in health and social care. 2011. Available at: http:// publications.nice.org.uk/ dementia-cg42/guidance
9. Swedish Medical Products Agency: Treatment of behavioral and psychological symptoms of dementia (BPSD). Uppsala, Sweden: Swedish Medical Products Agency (SMPA), 2008
10. Ballard CG, Gauthier S, Cummings JL, et al: Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009; 5:245-255
11. U.S. Food and Drug Administration: Risperdal (risperidone) tablets, boxed warning. Approved by FDA Center for Drug Evaluation and Research (CDER). Silver Spring, MD: FDA, 2008
12. Qaseem A, Snow W, Cross JT, et al: Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148:370-378
13. Ballard C, Howard R: Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci 2006; 7:492-500
14. De Deyn PP, Rabheru K, Rasmussen A, et al: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999; 53:946-955
15. Katz IR, Jeste DV, Mintzer JE, et al: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group. J Clin Psychiatry 1999; 60:107-115
16. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:191-210
17. Tariot PN, Solomon PR, Morris JC, et al: A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54:2269-2276
18. Raskind MA, Peskind ER, Wessel T, et al: Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54:2261-2268
19. Holmes C, Wilkinson D, Dean C, et al: The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004; 63:214-219
20. Howard RJ, Juszczak E, Ballard CG, et al: Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357:1382-1392
21. Cummings JL, Mega M, Gray K, et al: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314
22. Mega MS, Cummings JL: Frontal-subcortical circuits and neuropsychiatric disorders. J Neuropsychiatry Clin Neurosci 1994; 6: 358-370
23. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington DC, American Psychiatric Association, 1995
24. Folstein MF, Folstein SE, McHugh PR: "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
25. Morris JC: Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type. Int Psychogeriatr 1997; 9(suppl 1):173-176; discussion 177-178
26. Gay W: ECDEU Assessment Manual for Psychopharmacology, revised DHEW. Rockville, MD, National Institute of Mental Health, 1976
27. Simpson GM, Angus JW: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
28. Hughes CP, Berg L, Danziger WL, et al: A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140:566-572
29. Freund-Levi Y, Basun H, Cederholm T, et al: Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry 2008; 23:161-169
30. Gauthier S, Cummings J, Ballard C, et al: Management of behavioral problems in Alzheimer's disease. Int Psychogeriatr 2010; 22: 346-372
31. Ballard C: Agitation and psychosis in dementia. Am J Geriatr Psychiatry 2007; 15:913-917
32. Trinh NH, Hoblyn J, Mohanty S, et al: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289:210-216
33. Feldman H, Gauthier S, Hecker J, et al: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57:613-620
34. Rodda J, Morgan S, Walker Z: Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Int Psychogeriatr 2009; 21: 813-824
35. Rosler M, Retz W, Retz-Junginger P, et al: Effects of two-year treatment with the cholinesterase inhibitor rivastigmine on behavioural symptoms in Alzheimer's disease. Behav Neurol 1998; 11:211-216
36. Howard R, Philips P, Johnson T, et al: Determining the minimum clinically important differences for outcomes in the DOMINO trial. Int J Geriatr Psychiatry 2011; 26:812-817
37. Chiu MJ, Chen TF, Yip PK, et al: Behavioral and psychologic symptoms in different types of dementia. J Formos Med Assoc 2006; 105:556-562
38. Ballard C, Waite J, Birks J: Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Library 2008. DOI: 10.1002/14651858.CD003476.pub2